Skip to main content
. 2022 Apr 26;2022:6560154. doi: 10.1155/2022/6560154

Figure 3.

Figure 3

RAPGEF2 knockdown promotes tumor growth in HCC cancer xenografts. (a) Western blotting examination of MHCC97 cells transfected with either control (Ctrl) or RAPGEF2 shRNA. (b, c) The tumor growth curve and weights of the tumors were determined. (d, e) Fluorescence-activated cell sorting (FACS) study of CD56+CD3-natural killer cells in MHCC97 xenograft tumors with either control (Ctrl) or RAPGEF2 shRNA. Data represents the mean ± SD, n = 10 per group. P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.